Alcon #Academy21 Program to Showcase TOTAL30, Other Innovations that Meet Critical Patient and Practice Needs

Year after year, Alcon has delivered significant innovations across our Vision Care portfolio that help eye care professionals (ECPs) connect unmet patient and practice needs with industry-transforming products, said Sean Clark, General Manager, U.S.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Lundi, novembre 1, 2021
Information
Tags: 
Teens, Women, Parenting, Seniors, LGBTQ+, Men, Family, Consumer, Health, Optical, Ocular hypertension, Trial of the century, Lens (anatomy), Program, Glaucoma, American Academy, Retina, Quality of life, Propene, File, Private Securities Litigation Reform Act, Food, Cataract, Mark (given name), ECP, Approximation error, Water, Solution, CLEAR, Consumer, Science, Multicenter trial, Contact lens, NYSE, Drink, Joy, IOP, Ophthalmology, Wear, Monthly, Technology, Comfort, Academy, Exocrine gland, General manager, Forward-looking statement, Optometry, Duane syndrome, Electric Bond and Share Company v. Securities and Exchange Commission, Treatment, Medical device, Camera, Nightclub, Fused quartz, Telescopic sight, Silviculture, Renewable energy
Geotags: 
Texas, United States, LENS, BOSTON, MASSACHUSETTS
⚠generated by AI ↴
Résumé
Key Points: 
  • Year after year, Alcon has delivered significant innovations across our Vision Care portfolio that help eye care professionals (ECPs) connect unmet patient and practice needs with industry-transforming products, said Sean Clark, General Manager, U.S.
  • Our program is jam-packed with events centered around TOTAL30 and other important innovations that demonstrate our commitment to helping people see brilliantly.
  • The presentation will take place at The Westin Boston Seaport (425 Summer St, Boston, MA 02210) in Grand Ballroom B.
  • In a clinical study wherein patients (n=66) used CLEAR CARE solution for nightly cleaning, disinfecting, and storing; Alcon data on file, 2021.


Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will showcase leading innovations and clinical research findings at the American Academy of Optometry Annual Meeting (#Academy21) in Boston, Massachusetts, from November 3-6, 2021. The meeting will mark the official launch of TOTAL30®, the first-and-only monthly replacement Water Gradient contact lens that feels like nothing even on day 30,1 to the professional eye care community. Alcon’s engaging on-site program will feature events and more than a dozen clinical presentations around their most important eye care products, including the portfolio of permanent water surface technology contact lenses, dry eye and ocular health drops, and forthcoming innovations.

“Year after year, Alcon has delivered significant innovations across our Vision Care portfolio that help eye care professionals (ECPs) connect unmet patient and practice needs with industry-transforming products,” said Sean Clark, General Manager, U.S. Vision Care, Alcon. “We are thrilled to officially introduce TOTAL30 contact lenses to the optometry community at this year’s Academy meeting as an important option for their reusable lens patients seeking a more comfortable wearing experience. Our program is jam-packed with events centered around TOTAL30 and other important innovations that demonstrate our commitment to helping people see brilliantly.”

TOTAL30 Contact Lenses to Officially Debut with Scientific Presentations, Immersive ECP Evening Event and Lens Try-On

In August, Alcon launched TOTAL30 monthly replacement contact lenses, which are clinically shown to feel like nothing, even at day 30.1 The lens science was born from the Water Gradient technology of DAILIES TOTAL1®. The following events will give meeting attendees hands-on experiences with the design and science of the lens throughout the meeting:

  • The Science of Nothing Luncheon: Drs. Pamela Lowe and Erich Bauman. 12-1 p.m. ET. The presentation will take place at The Westin Boston Seaport (425 Summer St, Boston, MA 02210) in Grand Ballroom B.
  • The Joy of Nothing Launch Experience: Join us for an exciting, immersive launch event that will showcase the art and science behind TOTAL30's Water Gradient and CELLIGENT® technologies. Food and beverages will be provided. November 4, 2021, 6:30-8:30 p.m. ET at The Westin Boston Seaport in Grand Ballroom A. Register for the event here or visit Alcon booth #813.
  • TOTAL30 Lens Try-On: Stop by and experience first-hand why TOTAL30 is poised to be a game-changer in the reusable lens category and why it feels like nothing, even at day 30. Visit Alcon booth #813 during exhibit hall hours.

Additionally, there will be several data presentations taking place on Thursday, November 4, 2021, on the efficacy and clinical performance of TOTAL30, including:

  • Paper Presentation: Antimicrobial Efficacy of Contact Lens Care Products in the Presence of Lehfilcon A Contact Lenses. Presented by Dr. Manal M. Gabriel, 10:15-10:30 a.m. ET.
  • Poster Presentation: Consistent Comfort, Vision and Handling Performance of a New Monthly Replacement Spherical Contact Lens Over 3 Months of Daily Wear. Presented by Dr. Holly Lorentz, 4:30-6:30 p.m. ET.
  • Poster Presentation: Clinical Performance Evaluation of Lehfilcon A Monthly Replacement Silicone Hydrogel Toric Contact Lenses. Presented by Dr. Stephen Montaquila, 4:30-6:30 p.m. ET.
  • Poster Presentation: Clinical Performance of Two Monthly Replacement Spherical Contact Lenses. Presented by Dr. Gina Wesley, 4:30-6:30 p.m. ET.

Clinical and Survey Data Affirms Efficacy of PRECISION1 Water Surface Technology

Several clinical studies will be presented on November 4, 2021, highlighting PRECISION1® and PRECISION1 for Astigmatism, Alcon’s one-day contact lenses, made with permanent water surface technology that keeps moisture on the lens surface for patient comfort.2 Data highlights include:

  • Poster Presentation: Assessment of Evening Comfort and Vision with Water Surface Silicone Hydrogel Daily Disposable Lenses. Presented by Dr. Jennifer S. Fogt, 4:30-6:30 p.m. ET.
  • Poster Presentation: Practitioners Have High Satisfaction with SMARTSURFACE® TECHNOLOGY Daily Disposable Contact Lenses. Presented by Dr. Timothy Grant, 4:30-6:30 p.m. ET.
  • Poster Presentation: Contact Lens Wearers Have High Satisfaction with SMARTSURFACE® TECHNOLOGY Daily Disposable Contact Lenses. Presented by Dr. Timothy Grant, 4:30-6:30 p.m. ET.
  • Poster Presentation: Subjective Performance of Verofilcon A Daily Disposable Soft Contact Lens After 16 Hours of Wear. Presented by Dr. Colton M. Heinrich, 4:30-6:30 p.m. ET.
  • Poster Presentation: Assessment of U.S. Eye Care Professional and Consumer Satisfaction with Verofilcon A Daily Disposable Silicone Hydrogel Contact Lenses for Astigmatism. Presented by Dr. Carla Mack, 4:30-6:30 p.m. ET.
  • Poster Presentation: Evaluation of Wear Experience with Water Surface Lenses in Current Wearers of Silicone Hydrogel Planned Replacement Lenses. Presented by Dr. Ryan Rutschilling, 4:30-6:30 p.m. ET.
  • Poster Presentation: Survey of Patient and ECP Satisfaction with a New Daily Disposable Toric Contact Lens. Presented by Dr. Inma Perez-Gomez, 4:30-6:30 p.m. ET.

New Clinical Findings Affirm Efficacy of Products in Alcon’s Dry Eye and Ocular Health Portfolio

Alcon’s dry eye and ocular health portfolio features over-the-counter solutions and in-office devices, such as Systane® iLux®, Pataday® Once Daily Relief Extra Strength, and a variety of other brands, which support ocular surface health, dry eye, eye allergy itch symptom relief and more. Data highlights being presented at #Academy21 include:

  • November 4, 2021
    • Poster Presentation: Thermal Pulsation System in the Treatment of Meibomian Gland Dysfunction: A 12-Month, Randomized, Prospective Comparative Trial. Presented by Dr. David Kading, 4:30-6:30 p.m. ET.
    • Poster Presentation: Understanding Comfort Differences Between Pataday Once Daily Relief Extra Strength & Visine^ Allergy Eye Relief Multi-Action Drops. Presented by Dr. Christopher Lievens, 4:30-6:30 p.m. ET.
  • November 5, 2021
    • Poster Presentation: Understanding Ocular Comfort Differences Between Pataday Once Daily Relief Extra Strength and Alaway^. Presented by Dr. Amy Logan, 10 a.m.-12 p.m. ET.

Portfolio Expansions Will Deliver Industry Innovations for Unmet Patient, Practice Needs

In addition to the highlighted products and science noted above, Alcon is expanding its portfolio in 2022 with exciting new products, including:

  • DAILIES TOTAL1 for Astigmatism, the much-anticipated toric lens born from the trusted Water Gradient lens technology of DAILIES TOTAL1sphere and multifocal lenses.
  • Systane® Complete Multi-Dose Preservative Free, an all-in-one dry eye drop that delivers eight hours of dry eye symptom relief3 in a preservative-free formulation.
  • An upgraded dry eye device system that treats Meibomian Gland Dysfunction.

In addition, Alcon recently acquired exclusive U.S. commercialization rights to Simbrinza® (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, a fixed combination indicated in the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Visit Alcon booth #813 for important information on Alcon’s innovative products featured in this release.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. In particular, our expectations could be affected by uncertainties regarding the success of our separation and spin-off from Novartis. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.

Forward-looking statements in this press release speak only as of the date of its filing, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning more than seven decades, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases, and refractive errors. Our more than 23,000 associates are enhancing the quality of life through innovative products, partnerships with eye care professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

^ Trademarks are the property of their respective owners.

References

  1. In a clinical study wherein patients (n=66) used CLEAR CARE® solution for nightly cleaning, disinfecting, and storing; Alcon data on file, 2021.
  2. Cummings S, Giedd B, Pearson C. Clinical performance of a new daily disposable spherical contact lens. Optom Vis Sci. 2019;96: E Abstract 195375.
  3. Silverstein S, Yeu E, Tauber J, et al. Symptom Relief Following a Single Dose of Propylene Glycol-Hydroxypropyl Guar Nanoemulsion in Patients with Dry Eye Disease: A Phase IV, Multicenter Trial. Clin Ophthalmol. 2020; 14:3167-3177.

Connect with us on

Facebook

LinkedIn

Copyright: 
Copyright Business Wire 2021